EHMT2 and acute myeloid leukemia: Pharmacological and genetic targeting of G9a has been shown to be effective in slowing down the AML cell proliferation and reducing the LSC frequency in a mouse model and human AML cell lines due to the attenuation of HoxA9-dependent transcription [21–23].